Core Insights - The company reported annual revenue of approximately RMB 700 million to 720 million for the period ending December 31, 2025, representing a year-on-year growth of about 13.7% to 17.0% [1] Group 1: Revenue Growth - The continuous revenue growth is primarily attributed to the strong performance of all three product lines in the neurointervention business and the expanding market share in the transcatheter aortic valve replacement (TAVR) market, driven by the successful launch of the high-end TaurusMax 3D adjustable TAVR system [1] - All three product lines in neurointervention recorded robust revenue growth, reflecting strong performance of their core products [1] - The vascular access products saw revenue growth due to the increasing sales of the high-performance DCwire microcatheter, leading to a rapid increase in market share [1] Group 2: Product Performance - The hemorrhagic products benefited from the successful launch of the YonFlow blood flow-directed stent, which drove revenue growth for that product line [1] - Revenue growth in the ischemic product segment was mainly due to increased sales of the Syphonet thrombectomy stent and Tethys AS thrombectomy catheter [1] - Despite a price reduction in balloon dilation catheters following the implementation of volume-based procurement in the second half of 2025, sales volume significantly increased, particularly for the Fastunnel delivery balloon dilation catheter, keeping overall revenue stable compared to 2024 [1] Group 3: TAVR Market Expansion - The commercialized TAVR product portfolio was adopted in approximately 130 new hospitals during the reporting period, covering over 780 hospitals as of December 31, 2025 [2] - A total of approximately 3,900 units were implanted during the reporting period, representing a year-on-year growth of 14.4%, significantly exceeding the overall market growth rate [2] - With the registration application for the TaurusTrio transcatheter aortic valve system approved by the National Medical Products Administration in December 2025, the company anticipates a full commercialization in the Chinese aortic regurgitation market [2]

Core Viewpoint - CICC maintains the profit forecast for Peijia Medical-B (09996) for 2025/26 and keeps the outperform rating unchanged, raising the target price by 25% to HKD 10, indicating an 18% upside potential from the current price [1] Group 1: TAVR Business Performance - TAVR (Transcatheter Aortic Valve Replacement) revenue for 1H25 reached RMB 162 million, a year-on-year increase of 25%, with terminal implant volume exceeding 2,050 units, up 19.8% [2] - The company achieved its first commercial profitability in the valve segment with RMB 29 million, while the R&D expense ratio decreased by 16.7 percentage points to 33.5% [2] - Three important in-development products, including regurgitant TAVR, long-lasting TAVR, and mitral valve clip, have completed registration clinical follow-ups, with expected approvals between the end of 2025 and mid-2026 [2] Group 2: Neurointervention Business Outlook - Neurointervention revenue for 1H25 was RMB 192 million, a year-on-year increase of 12%, with segment profit reaching RMB 41 million, up 42.4%, and a net profit margin of 21% [3] - The DCwire micro-guidewire has successfully gained traction domestically, with revenue increasing by 140%, and is expected to receive US 510(k) approval by the end of 2025 [3] - The company remains optimistic about the second half of 2025, anticipating a sequential acceleration in growth, with a projected annual revenue growth of 20-30% for the neurointervention segment [3]

Core Viewpoint - 中金 maintains its earnings forecast for Peijia Medical-B (09996) for 2025/26 and keeps its outperform rating unchanged, citing a recovery in the Hong Kong pharmaceutical sector and the expected approval of multiple new products by mid-2026 [1] Group 1: TAVR Business Performance - In 1H25, TAVR (transcatheter aortic valve replacement) revenue reached 162 million HKD, a year-on-year increase of 25%, with over 2,050 units implanted, up 19.8% [2] - The company achieved its first commercial profitability in the valve segment with a profit of 29 million HKD, and the R&D expense ratio decreased by 16.7 percentage points to 33.5% [2] - The company anticipates that three important products, including regurgitant TAVR, long-acting TAVR, and mitral valve clips, will be approved between the end of 2025 and mid-2026, potentially reshaping the competitive landscape in China [2] Group 2: Neurointervention Business Outlook - In 1H25, neurointervention revenue was 192 million HKD, a year-on-year increase of 12%, with segment profit reaching 41 million HKD, up 42.4%, resulting in a net profit margin of 21% [3] - The domestic launch of DCwire micro-guidewires saw a revenue increase of 140%, and the company expects to obtain US 510(k) approval for this product by the end of 2025 [3] - The company remains optimistic about accelerating growth in the neurointervention segment in 2H25, projecting a year-on-year revenue growth of 20-30% for the entire year of 2025 [3]

Group 1 - The company reported a revenue of approximately 353 million yuan for the first half of 2025, representing a year-on-year growth of 17.3% [1] - Gross profit reached 248 million yuan, with a year-on-year increase of 13.14% [1] - Research and development expenses were about 116 million yuan, showing a year-on-year growth of 15.1% [1] Group 2 - The sustainable revenue growth is primarily attributed to strong sales growth in transcatheter valve therapy and neurointervention businesses [1] - Sales revenue from TAVR-related products increased by 24.0% to 162 million yuan, driven by market share gains in China's transcatheter aortic valve replacement market and a shift towards newly launched high-end products [1] - The total number of implants exceeded 2,050 units during the reporting period, reflecting a year-on-year growth of approximately 18.8%, surpassing market growth [1] Group 3 - Sales revenue from neurointervention products rose by 12.2% to 192 million yuan, driven by deeper market penetration of existing products and the successful launch of the newly approved YonFlow blood flow-directed mesh stent [1] - The DCwire microcatheter, launched commercially in 2024, significantly expanded market share with a revenue growth of nearly 140% [2] - The YonFlow blood flow-directed mesh stent received regulatory approval in April 2025 and achieved its first commercial implant by June 2025, with procurement completed in over 20 provinces [2]

Core Insights - The article highlights the significant advancements and market position of Jiangsu Suzhou-based company, Peijia Medical, particularly its subsidiary, Gaki Bio, in the neuro-interventional medical device sector [1][2][3] Group 1: Company Overview - Gaki Bio, established in 2006, has developed China's first commercialized spring coil and offers a comprehensive range of products addressing hemorrhagic, ischemic, and access solutions [1] - The company is expected to break even in 2024, marking an 18-year journey from obscurity to industry leadership [1] Group 2: Product Development and Market Strategy - The Syphonet thrombectomy stent, launched in February 2022, quickly became the market leader among domestic products, showcasing Gaki Bio's effective research and development strategy [2] - Gaki Bio's approach involves launching a complete suite of products simultaneously to address all surgical needs, enhancing the usability and effectiveness of their devices [2] - The Fastunnel delivery balloon catheter, approved in May 2022, features an integrated design that simplifies complex procedures, reducing the number of steps required in surgeries [3][4] Group 3: Innovation and Clinical Needs - Gaki Bio has developed 16 products that have received approval for sale, with plans to submit 5 to 6 additional registration applications this year, focusing on unmet clinical needs [4] - The company has adopted a "medical-engineering collaboration" innovation methodology, which has proven effective in the neuro-interventional device market [3][4] Group 4: Operational Efficiency and Supply Chain - Gaki Bio has achieved over 90% localization in its supply chain, sourcing more than 90% of its raw materials from domestic suppliers, which enhances cost efficiency and responsiveness [5][6] - The company has implemented lean production standards, resulting in increased operational efficiency and a reported gain of over 20 million yuan in product development [5][6]